Literature DB >> 28050491

Current Development of Anti-Cancer Drug S-1.

Pratima Chhetri1, Anil Giri1, Suraj Shakya1, Sujana Shakya1, Binaya Sapkota1, K C Pramod1.   

Abstract

S-1 is a novel oral fluoropyrimidine derivative, widely used for treating gastric, pancreatic, lung, head, neck and breast carcinomas. It is designed to enhance the clinical utility of an oral fluoropyrimidine and is associated with low gastrointestinal toxicity. S-1 consists of three pharmacological agents (at a molar ratio of 1:0.4:1)-Tegafur (FT), a prodrug of 5-Fluorouracil (5-FU), 5-Chloro-2-4-Dihydroxypyridine (CDHP), which inhibits the activity of Dihydropyrimidine Dehydrogenase (DPD) and Oxonic Acid (Oxo), which reduces Gastrointestinal (GI) toxicity of 5-FU. The present article reviews the current development of clinical study of S-1.

Entities:  

Keywords:  Cisplatin; Irinotecan; Paclitaxel; Pharmacokinetics

Year:  2016        PMID： 28050491      PMCID： PMC5198444          DOI： 10.7860/JCDR/2016/19345.8776

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN： 0973-709X


  32 in total

Review 1.  The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.

Authors:  Hans Lennernäs; Bertil Abrahamsson
Journal:  J Pharm Pharmacol       Date:  2005-03       Impact factor: 3.765

2.  A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study).

Authors:  T Yoshikawa; K Omura; O Kobayashi; A Nashimoto; A Takabayashi; T Yamada; H Yamaue; M Fujii; T Yamaguchi; T Nakajima
Journal:  Eur J Surg Oncol       Date:  2010-06       Impact factor: 4.424

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.

Authors:  T Komatsu; H Yamazaki; N Shimada; S Nagayama; Y Kawaguchi; M Nakajima; T Yokoi
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

5.  Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.

Authors:  M M Borner; P Schoffski; R de Wit; F Caponigro; G Comella; A Sulkes; G Greim; G J Peters; K van der Born; J Wanders; R F de Boer; C Martin; P Fumoleau
Journal:  Eur J Cancer       Date:  2002-02       Impact factor: 9.162

6.  Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.

Authors:  G J Peters; P Noordhuis; A B P Van Kuilenburg; J H Schornagel; H Gall; S L Turner; M S Swart; D Voorn; A H Van Gennip; J Wanders; U Holwerda; K Smid; G Giaccone; P Fumoleau; C J Van Groeningen
Journal:  Cancer Chemother Pharmacol       Date:  2003-05-09       Impact factor: 3.333

7.  Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age.

Authors:  Dae Young Zang; Dae Hyun Yang; Hae Wan Lee; Se Won Hwang; Hun Ho Song; Joo Young Jung; Jung Hye Kwon; Hyo Jung Kim; Jung Han Kim; Sa Rah Park; Min-Jeong Kim; Kyung Mi Jang; Choong Kee Park; Jong Hyeok Kim; Bong Hwa Lee
Journal:  Cancer Chemother Pharmacol       Date:  2008-05-15       Impact factor: 3.333

8.  A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.

Authors:  Akihiro Nakajo; Shuichi Hokita; Sumiya Ishigami; Futoshi Miyazono; Tadaaki Etoh; Masahiro Hamanoue; Shigeho Maenohara; Toshimitsu Iwashita; Hideaki Komatsu; Kiyoharu Satoh; Kuniaki Aridome; Satoshi Morita; Shoji Natsugoe; Hiroya Takiuchi; Shyuji Nakano; Yoshihiko Maehara; Junichi Sakamoto; Takashi Aikou
Journal:  Cancer Chemother Pharmacol       Date:  2008-03-04       Impact factor: 3.333

Review 9.  S-1: a promising new oral fluoropyrimidine derivative.

Authors:  Muhammad Wasif Saif; Kostas N Syrigos; Nikos A Katirtzoglou
Journal:  Expert Opin Investig Drugs       Date:  2009-03       Impact factor: 6.206

10.  Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.

Authors:  M Inokuchi; T Yamashita; H Yamada; K Kojima; W Ichikawa; Z Nihei; T Kawano; K Sugihara
Journal:  Br J Cancer       Date:  2006-04-24       Impact factor: 7.640
View more
  12 in total

1.  Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study.

Authors:  Ying Lu; Haixin Huang; Hui Yang; Xiaohua Hu; Meilian Liu; Changjie Huang; Xianbin Feng; Xishan Chen; Zhou Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-08       Impact factor: 4.322

Review 2.  The treatment of resectable gastric cancer: a literature review of an evolving landscape.

Authors:  Iris Tung; Arvind Sahu
Journal:  J Gastrointest Oncol       Date:  2022-04

3.  5-Chloro-2,4-dihydroxypyridine, CDHP, prevents lung metastasis of basal-like breast cancer cells by reducing nascent adhesion formation.

Authors:  Junji Itou; Hiroshi Tsukihara; Mamoru Nukatsuka; Masakazu Toi; Teiji Takechi
Journal:  Cancer Med       Date:  2018-01-22       Impact factor: 4.452

Review 4.  Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature.

Authors:  Chu Zhang; Xiang Wang; Miao Zhang; Dong Liu; Dun-Peng Yang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

5.  The combination of apatinib and S-1 for the treatment of advanced gastric cancer in China: A meta-analysis of randomized controlled trials.

Authors:  Yan Liu; Changchun Zhou; Kai Zhang; Yikuan Feng; Ruihua Zhang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

6.  Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.

Authors:  Hae Won Lee; Sook Jin Seong; Woo Youl Kang; Boram Ohk; Mi-Ri Gwon; Bo Kyung Kim; Seungil Cho; Kyunghee Cho; Yong Kyung Sung; Young-Ran Yoon; Jong Gwang Kim
Journal:  Drug Des Devel Ther       Date:  2019-09-03       Impact factor: 4.162

7.  Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma.

Authors:  Jingfeng Zong; Hanchuan Xu; Bijuan Chen; Qiaojuan Guo; Yun Xu; Chuanben Chen; Youliang Weng; Wei Zheng; Jianji Pan; Shaojun Lin
Journal:  Radiat Oncol       Date:  2019-10-22       Impact factor: 3.481

8.  Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis.

Authors:  Chih-Chieh Yen; Yan-Shen Shan; Ying-Jui Chao; Ting-Kai Liao; I-Shu Chen; Hsuan-Yi Huang; I-Ting Liu; Chia-Jui Yen
Journal:  BMC Cancer       Date:  2021-07-09       Impact factor: 4.430

9.  Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial.

Authors:  Yan Shi; Sui Zhang; Quanli Han; Jie Li; Huan Yan; Yao Lv; Huaiyin Shi; Rong Liu; Guanghai Dai
Journal:  Oncotarget       Date:  2017-09-28

Review 10.  Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians.

Authors:  Dimitrios Giannis; Dimitrios Moris; Andrew S Barbas
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.